Thanks. You just made me buy. Little rule of mine: always do the opposite of the very stupid. Then put them on ignore.
ja didn't intend to imply it was new news... but its still fact and this is a quiet little place to stick my dd. The CEO bio is old fact too, but matters to me. Lots. I like his record.
The integration of the acquisition is sort of old news too but will drive this this Q.
I am pretty sure there is a Ignore button on your screen if I am boring ya.
Searching for something beat up from tax loss selling that looks to have good prospects for a 2014 recovery. Bought some @ 1.17 about 5 minutes before the close. No time left for any more sellers. Not a huge position, but enough to benefit from any recovery.
Also bought some CDXS today @ 1.38 about the same time.
Hope we all do well in '14. HAPPY NEW YEAR and success to all in the New Year.
Thomas A. Bologna joined Response Genetics as our Chief Executive Officer in December 2011.
From April 2006 until joining Response Genetics, Mr. Bologna served as President and Chief Executive Officer of Orchid Cellmark, Inc., a NASDAQ-listed corporation and a leading service provider of DNA identity testing.
Prior to joining Orchid Cellmark, Mr. Bologna was President, Chief Executive Officer and a member of the board of the venture-backed Quorex Pharmaceuticals, Inc., where he orchestrated a successful sale to Pfizer Inc.
Prior to leading Quorex, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Ostex International, Inc., a NASDAQ-listed biotechnology company that developed and commercialized disease management products with a focus on osteoporosis. Mr. Bologna oversaw the sale of Ostex to Alere Inc. (formally Inverness Medical Innovations).
Mr. Bologna’s prior experience includes serving as President and Chief Executive Officer of Scriptgen Pharmaceuticals, Inc., a Boston biotechnology start-up company.
Before leading Scriptgen, Mr. Bologna was Chairman of the Board, President and Chief Executive Officer of Gen-Probe, Incorporated, a global leader in the development, manufacture and marketing of molecular diagnostic products. He led Gen-Probe through its initial public offering on NASDAQ and oversaw its subsequent sale to Chugai Pharmaceutical Co., Ltd.
Mr. Bologna has also held senior-level positions with Becton Dickinson & Company and Warner-Lambert Company (Pfizer), two leading Fortune 500 healthcare companies.
Mr. Bologna served as President of the Becton Dickinson Diagnostic Instrument Systems Division and as a Vice President of the Warner-Lambert Company.
OXBT was a monster runner this year; I bought it at $2.02 and sold over $6.00. Making $16,000 in just a couple days, man I would have never bought it if Hulk Alerts never alerted me about it at $2.00 recommend everyone to check them out just copy and past Hulk Alerts into Google and search
Back in @ 1.46. Position is twice the size of my previous one. This is a company I want to own at this time. Looks like a good year shaping up.
"The offering was done by National in one day. The entire 4.6 m was resolved at 1.20. They are locked and loaded. There is enough powder in the keg to get this thing going. The management team is progressive, available and aware of the share price and remain very positive about the outlook of the company for 2014" ...
if you chose to look through old messages you could understand why ... if you are scared investing here buy some ebay or facebook ...
Sentiment: Strong Buy